Novel Therapies in Advanced Prostate Cancer

EAU-EBU Update Series

Volumn 4, Issue 4, 2006, Pages 161-170

  Sowery, Richard D ^a   So, Alan I ^a   Gleave, Martin E ^a  

^a VANCOUVER GENERAL HOSPITAL   (Canada)

Author keywords

Advanced prostate cancer; Novel therapies; Review

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; BISPHOSPHONIC ACID DERIVATIVE; CANCER VACCINE; DOCETAXEL; ENDOTHELIN RECEPTOR ANTAGONIST; EPOTHILONE DERIVATIVE; ESTRAMUSTINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; GTI 2501; HYDROCORTISONE; INTERFERON; IXABEPILONE; MITOXANTRONE; MONOCLONAL ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT; OBLIMERSEN; OGX 011; OGX 427; PREDNISONE; PROSTVAC F; PROVENGE; TAXANE DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIRUS VACCINE; WARFARIN; ZOLEDRONIC ACID;

ACUTE PHASE RESPONSE; ADVANCED CANCER; ALOPECIA; BONE MARROW SUPPRESSION; BONE NECROSIS; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DRUG EFFICACY; DRUG FATALITY; DRUG FEVER; DRUG HALF LIFE; DRUG INDUCED HEADACHE; FATIGUE; FEBRILE NEUTROPENIA; FLUSHING; HUMAN; INFECTION; JAW DISEASE; MALE; MUSCULOSKELETAL DISEASE; MYALGIA; NAIL DISEASE; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL EDEMA; PROSTATE CANCER; REVIEW; RHINITIS; SENSORY NEUROPATHY; SEPSIS; TERATOGENICITY; THROMBOEMBOLISM;

EID: 33746225486     PISSN: 18712592     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eeus.2006.05.001     Document Type: Review

References (41)

1. Yagoda A., and Petrylak D. Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer 71 (1993) 1098-1099
2. Tannock I.F., de Wit R., Berry W.R., Horti J., Pluzanska A., Chi K.N., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351 (2004) 1502-1512
3. Petrylak D.P., Tangen C.M., Hussain M.H.A., Lara Jr. P.N., Jones J.A., Taplin M.E., et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351 (2004) 1513-1520
4. Sonpavde G., Hutson T.E., and Berry W.R. Hormone refractory prostate cancer: management and advances. Cancer Treat Rev 32 (2006) 90-100
5. Tannock I.F., Osaba D., Stockler M.R., Ernst D.S., Neville A.J., Moore M.J., et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: A Canadian randomized trial with palliative end points. J Clin Oncol 14 (1996) 1756-1764
6. Kantoff P.W., Halabi S., Conaway M., et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the Cancer and Leukemia Group B 9182 study. J Clin Oncol 17 (1999) 2506-2513
7. Galsky M.D., Small E.J., Oh W.K., Chen I., Smith D.C., Colevas A.D., et al. Multi-institutional randomized phase II trial of the epothilone B analogue ixabepilone (BMS-247550) with or without estramustine phosphate in patients with castrate metastatic prostate cancer. J Clin Oncol 23 (2005) 1439-1446
8. Hussain M., Tangen C.M., Lara Jr. P.N., Vaishampayan U.N., Petrylak D.P., Colevas A.D., et al., Soutwest Oncology Group. Ixabepilone (Epothilone B analogue BMS-247550) is active in chemotherapy-naïve patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111. J Clin Oncol 23 (2005) 8724-8729
9. Lee M.V., Fong E.M., Singer F.R., and Lee R.V. Bisphosphonate treatment inhibits the growth of prostate cancer cells. Cancer Res 61 (2001) 2602-2608
10. Saad F., Gleason D.M., Murray R., Tchekmedyian S., Venner P., and Lacombe L. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 96 (2004) 879-882
11. Smith M.R., Eastham J., Gleason D.M., Shasha D., Tchekmedyian S., and Zinner N. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol (2003) 2008-2012
12. Small EJ, Schellhammer PF, Higano CS, Neumanaitis J, Valone F, Hershberg R. Results of a placebo-controlled phase III trial of immunotherapy with APC8015 for patients with hormone refractory prostate cancer (HRPC). ASCO 2005, abstract 4500.
13. Simons J., Higano C., and Corman J. A phase I/II trial of high dose allogeneic GM-CSF gene-transduced prostate cancer cell line vaccine in patients with metastatic hormone-refractory prostate cancer. Proc Am Soc Clin Oncol 22 (2003) 166 abstract 667
14. Small E, Higano C, Smith D. A phase 2 study of an allogeneic GM-CSF genetransduced prostate cancer cell line vaccine in patients with metastatic hormonerefractory prostate cancer (HRPC). Proc Am Soc Clin Oncol 2004, abstract 4565.
15. R-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM™) in patients with prostate cancer. J Transl Med 3 (2006) 1
16. Bander N.H., Milowsky M.I., Nanus D.M., Kostakoglu L., Vallabhajosula S., and Goldsmith S.J. Phase I trial of 177Lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. J Clin Oncol 23 (2005) 4591-4601
17. Small E.J., Reese D.M., Um B., Whisenant S., Dixon S.C., and Figg W.D. Therapy of advanced prostate cancer with granulocyte macrophage colony-stimulating factor. Clin Cancer Res 5 (1999) 1738-1744
18. Rini B.I., Weinberg V., Bok R., and Small E.J. Prostate-specific antigen kinetics as a measure of the biologic effect of granulocyte-macrophage colony-stimulating factor in patients with serologic progression of prostate cancer. J Clin Oncol 21 (2003) 9-105
19. Gleave M.E., and Monia B.P. Antisense therapy for cancer. Nat Rev Canc 5 (2005) 468-479
20. Eder I.E., Hoffmann J., Rogatsch H., Schafer G., Zopf D., Bartsch G., et al. Inhibition of LNCaP prostate tumor growth in vivo by an antisense oligonucleotide directed against the human androgen receptor. Cancer Gene Ther 9 (2002) 117-125
21. Gleave M., Miyake H., and Chi K. Beyond simple castration: targeting the molecular basis of treatment resistance in advanced prostate cancer. Cancer Chemother Pharmacol 56 (2005) 47-57
22. Chi K.N., Gleave M.E., Klasa R., Murray N., Bryce C., Lopes de Menezes D.E., et al. A phase I dose-finding study of combined treatment with an antisense Bcl-2 oligonucleotide (Genasense) and mitoxantrone in patients with metastatic hormone-refractory prostate cancer. Clin Cancer Res 7 (2001) 3920-3927
23. Tolcher A.W., Kuhn J., Schwartz G., Patnaik A., Hammond L.A., Thompson I., et al. A phase I pharmacokinetic and biological correlative study of oblimersen sodium (genasense G3139), an antisense oligonucleotide to the bcl-2 mRNA, and of docetaxel in patients with hormone-refractory prostate cancer. Clin Cancer Res 10 (2004) 5048-5057
24. Tolcher A.W., Chi K., Kuhn J., Gleave M., Patnaik A., Takimoto C., et al. A phase II, pharmacokinetic and biological correlative study of oblimersen sodium and docetaxel in patients with hormone-refractory prostate cancer. Clin Cancer Res 11 (2005) 3854-3861
25. Steinberg J., Oyasu R., Lang S., Sintich S., Rademaker A., Lee C., et al. Intracellular levels of SGP-2 (Clusterin) correlate with tumor grade in prostate cancer. Clin Cancer Res 3 (1997) 1707-1711
26. July L.V., Akbari M., Zellweger T., Jones E.C., Goldenberg S.L., and Gleave M.E. Clusterin expression is significantly enhanced in prostate cancer cells following androgen withdrawal therapy. Prostate 50 (2002) 179-188
27. Miyake H., Nelson C., Rennie P.S., and Gleave M.E. Testosterone-repressed prostate message-2 is an antiapoptotic gene involved in progression to androgen independence in prostate cancer. Cancer Res 60 (2000) 170-176
28. Miyake H., Chi K.N., and Gleave M.E. Antisense TRPM-2 oligodeoxynucleotides chemosensitize human androgen-independent PC-3 prostate cancer cells both in vitro and in vivo. Clin Cancer Res 6 (2000) 1655-1663
29. Zellweger T., Chi K., Miyake H., Adomat H., Kiyama S., Skov K., et al. Enhanced radiation sensitivity in prostate cancer by inhibition of the cell survival protein clusterin. Clin Cancer Res 8 (2002) 3276-3284
30. Zellweger T., Miyake H., Cooper S., Chi K., Conklin B.S., Monia B.P., et al. Antitumor activity of antisense clusterin oligonucleotides is improved in vitro and in vivo by incorporation of 2′-O-(2-methoxy)ethyl chemistry. J Pharmacol Exp Ther 298 (2001) 934-940
31. Chi K.N., Eisenhauer E., Fazli L., Jones E.C., Goldenberg S.L., Powers J., et al. A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2′-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer. J Natl Cancer Inst 97 (2005) 1287-1296
32. Chi KN, Eisenhauer E, Siu L, Hirte H, Hotte S, Chia S, et al. A phase I study of a second generation antisense oligonucleotide to clusterin (OGX-011) in combination with docetaxel: NCIC CTG IND.154. ASCO 2005, abstract 3085.
33. Nelson J., Bagnato A., Battistini B., and Nisen P. The endothelin axis: emerging role in cancer. Nat Rev Cancer 3 (2003) 110-116
34. Carducci M.A., Padley R.J., Breul J., Vogelzang N.J., Zonnenberg B.A., Daliani D.D., et al. Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial. J Clin Oncol 21 (2003) 679-689
35. Carducci M, Nelson JB, Saad F. Effects of atrasentan on disease progression and biological markers in men with metastatic hormone-refractory prostate cancer: Phase 3 study. Proc Am Soc Clin Oncol 2004, abstract 4508.
36. Vogelzang NJ, Nelson JB, Schulman CC, Dearnealy DP, Saad F, Sleep DJ, et al. Meta-analysis of clinical trials of atrasentan 10 mg in metastatic hormone-refractory prostate cancer. ASCO 2005, abstract 4563.
37. Ferrara N., and Kerbel R.S. Angiogenesis as a therapeutic target. Nature 438 (2005) 967-974
38. Figg W.D., Dahut W., Duray P., Hamilton M., Tompkins P., and Steinberg S.M. A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer. Clin Cancer Res 7 (2001) 1888-1893
39. Figg W.D., Arlen P., Gulley J., Fernandez P., Noonan M., and Fedenko K.A. A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer. Semin Oncol 28 (2001) 62-66
40. Picus J, Halabi B, Rini N, Vogelzang N, Wheng Y, Kaplan E, et al. The use of bevacizumab with docetaxel and estramustine in hormone refractory prostate cancer: Initial results of CALGB 90006. ASCO 2003;1578, abstract 203.
41. Oh WK, Halabi S, Kelly WK, Godley PA, Werner C, Kantoff PW, et al. Cancer and Leukemia Group B. A phase II study of estramustine, docetaxel and carboplatin (EDC) with G-CSF support in men with hormone refractory prostate cancer (HRPC): CALGB 99813. ASCO 2002, abstract 779.